Angiotensin II human
Based on 224 publication(s) in Google Scholar
Angiotensin II (Angiotensin II) is a vasoconstrictor and a major bioactive peptide of the renin/angiotensin system. Angiotensin II human plays a central role in regulating human blood pressure, which is mainly mediated by interactions between Angiotensin II and the G-protein-coupled receptors (GPCRs) Angiotensin II type 1 receptor (AT1R) and Angiotensin II type 2 receptor (AT2R). Angiotensin II human stimulates sympathetic nervous stimulation, increases aldosterone biosynthesis and renal actions. Angiotensin II human induces growth of vascular smooth muscle cells, increases collagen type I and III synthesis in fibroblasts, leading to thickening of the vascular wall and myocardium, and fibrosis. Angiotensin II human also induces apoptosis. Angiotensin II induces capillary formation from endothelial cells via the LOX-1 dependent redox-sensitive pathway.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.98%
- CAS No.: 4474-91-3
- Formule: C50H71N13O12
- Masse moléculaire:1046.18
-
Stockage:
Sealed storage, away from moisture and light, under nitrogen.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)
Publications Citing Use of MedChemExpress (MCE) Angiotensin II human
More- Cell Metab. 2026 Feb 3;38(2):370-387.e10. [Abstract]
- Cell Stem Cell. 2025 Sep 4;32(9):1390-1402.e9. [Abstract]
- Nat Aging. 2024 Mar;4(3):396-413. [Abstract]
- Cell Host Microbe. 2022 Oct 12;30(10):1450-1463.e8. [Abstract]
- Circ Res. 2020 Mar 13;126(6):e15-e29. [Abstract]
- ACS Nano. 2022 Aug 23;16(8):12553-12568. [Abstract]
- Nat Commun. 2025 Jul 1;16(1):5927. [Abstract]
- Nat Commun. 2023 Sep 21;14(1):5891. [Abstract]
- Nat Commun. 2022 Jul 25;13(1):4278. [Abstract]
- Cell Death Differ. 2025 Nov 11. [Abstract]
- Acta Pharm Sin B. 2025 Mar;15(3):1643-1658. [Abstract]
- Sci Transl Med. 2024 May;16(745):eadh1763. [Abstract]
- Acta Pharm Sin B. 2022 Jan;12(1):135-148. [Abstract]
- Sci Transl Med. 2021 Jul 21;13(603):eaaz4959. [Abstract]
- Adv Sci (Weinh). 2025 Jun 23:e07365. [Abstract]
- Theranostics. 2026 Feb 4;16(8):4452-4470. [Abstract]
- Chem Eng J. 2026 Feb 17.
- Sci Adv. 2025 Jun 27;11(26):eadu8422. [Abstract]
- Med. 2026 Mar 27:101078. [Abstract]
- Engineering. 2025 Nov 14.
- Biomark Res. 2025 Mar 29;13(1):53. [Abstract]
- Cell Rep Med. 2025 Sep 16;6(9):102328. [Abstract]
- Pharmacol Res. 2025 Apr:214:107675. [Abstract]
- Pharmacol Res. 2021 Feb:164:105391. [Abstract]
- Cell Mol Biol Lett. 2022 Jul 14;27(1):55. [Abstract]
- Int J Biol Sci. 2025 Apr 22;21(7):3061-3080. [Abstract]
- Food Chem. 2025 Dec 2:499:147383. [Abstract]
- Ultrason Sonochem. 2025 Oct 20:123:107642. [Abstract]
- J Nucl Med. 2025 Sep 11:jnumed.124.268860. [Abstract]
- J Pharm Anal. 2026 Jan 22.
- Chin Chem Lett. 2023 Mar;34(3):107522. [Abstract]
- View. 2025 Oct 28.
- Int J Biol Macromol. 2025 Aug;320(Pt 4):146018. [Abstract]
- Acta Pharmacol Sin. 2025 Sep 2. [Abstract]
- Acta Pharmacol Sin. 2025 Apr;46(4):922-939. [Abstract]
- Acta Pharmacol Sin. 2025 May;46(5):1275-1288. [Abstract]
- Acta Pharmacol Sin. 2024 Aug;45(8):1618-1631. [Abstract]
- Acta Pharmacol Sin. 2022 Oct;43(10):2573-2584. [Abstract]
- Acta Pharmacol Sin. 2021 Jul;42(7):1090-1100. [Abstract]
- EMBO Mol Med. 2025 Dec;17(12):3555-3585. [Abstract]
- Phytomedicine. 2025 Oct:146:157101. [Abstract]
- Phytomedicine. 2025 May:140:156545. [Abstract]
- Phytomedicine. 2024 Apr:126:155200. [Abstract]
- Phytomedicine. 2021 Oct:91:153675. [Abstract]
- Hypertension. 2025 Sep;82(9):1505-1519. [Abstract]
- Br J Pharmacol. 2025 Aug 24. [Abstract]
- J Transl Med. 2025 Nov 13;23(1):1282. [Abstract]
- Biomed Pharmacother. 2023 Dec:168:115729. [Abstract]
- Biomed Pharmacother. 2023 Sep:165:115125. [Abstract]
- Cell Death Discov. 2022 May 4;8(1):246. [Abstract]
- Cell Death Discov. 2022 Apr 5;8(1):167. [Abstract]
- Clin Transl Med. 2023 Mar;13(3):e1213. [Abstract]
- Elife. 2022 Jun 22:11:e74519. [Abstract]
- Phytother Res. 2026 May;40(5):2878-2894. [Abstract]
- Cell Biosci. 2025 Oct 22;15(1):143. [Abstract]
- Cell Mol Life Sci. 2023 Jun 20;80(7):184. [Abstract]
- EMBO Rep. 2023 Mar 6;24(3):e56135. [Abstract]
- Talanta. 2024 Oct 14:282:127045. [Abstract]
- JCI Insight. 2020 Jul 9;5(13):e138505. [Abstract]
- Food Biosci. 2025 Mar.
- Chin Med. 2025 Oct 23;20(1):180. [Abstract]
- Atherosclerosis. 2025 Apr 26:405:119216. [Abstract]
- Acta Physiol. 2026 Apr;242(4):e70189. [Abstract]
- Biochem Pharmacol. 2025 Aug 8;242(Pt 1):117218. [Abstract]
- Biochem Pharmacol. 2025 Aug 19;242(Pt 1):117252. [Abstract]
- Biochem Pharmacol. 2025 Jul 26;242(Pt 1):117190. [Abstract]
- Biochem Pharmacol. 2025 Apr:234:116800. [Abstract]
- Biochem Pharmacol. 2024 Jan:219:115967. [Abstract]
- Biochem Pharmacol. 2023 Jul:213:115631. [Abstract]
- Mol Cell Proteomics. 2025 Feb 5:100922. [Abstract]
- Mar Drugs. 2025 Sep 19;23(9):365. [Abstract]
- Inflammopharmacology. 2025 Mar 27. [Abstract]
- Cells. 2025 Apr 11;14(8):579. [Abstract]
- Commun Biol. 2025 Nov 29. [Abstract]
- Commun Biol. 2025 Jul 5;8(1):1009. [Abstract]
- Life Sci. 2022 Oct 15:307:120878. [Abstract]
- Inflammation. 2026 May 12.
- J Nutr Biochem. 2025 Dec 6:150:110211. [Abstract]
- J Nutr Biochem. 2024 Apr:126:109578. [Abstract]
- Int J Mol Sci. 2023 Jun 29;24(13):10839. [Abstract]
- Biomolecules. 2026 Jan 7;16(1):98. [Abstract]
- Pharmaceuticals (Basel). 2025 Apr 9;18(4):553. [Abstract]
- Biomolecules. 2024 Jun 19;14(6):726. [Abstract]
- Biomolecules. 2022 Oct 27;12(11):1574. [Abstract]
- Front Pharmacol. 2022 Aug 17:13:942769. [Abstract]
- Front Pharmacol. 2021 Jun 24:12:684375. [Abstract]
- Eur J Pharmacol. 2025 Dec 15:1009:178388. [Abstract]
- Int Immunopharmacol. 2025 Sep 23:162:115163. [Abstract]
- J Mol Cell Cardiol. 2025 May:202:133-143. [Abstract]
- Eur J Pharmacol. 2025 Feb 1:177346. [Abstract]
- Eur J Pharmacol. 2024 Apr 5:968:176397. [Abstract]
- Int Immunopharmacol. 2024 Feb 15:128:111554. [Abstract]
- Am J Physiol Cell Physiol. 2024 Feb 1;326(2):C400-C413. [Abstract]
- Philos Trans R Soc Lond B Biol Sci. 2023 Jun 19;378(1879):20220173. [Abstract]
- Int Immunopharmacol. 2023 Jun:119:110197. [Abstract]
- Int Immunopharmacol. 2023 Mar:116:109795. [Abstract]
- Int Immunopharmacol. 2022 Nov:112:109218. [Abstract]
- Am J Physiol Cell Physiol. 2020 May 1;318(5):C913-C930. [Abstract]
- Hypertens Res. 2023 Jul;46(7):1759-1770. [Abstract]
- J Physiol. 2025 May 11. [Abstract]
- Eur J Cell Biol. 2024 May 28;103(2):151427. [Abstract]
- FASEB J. 2026 Feb 15;40(3):e71524. [Abstract]
- Mol Nutr Food Res. 2026 Jan;70(1):e70371. [Abstract]
- J Cell Mol Med. 2026 Jan;30(1):e70971. [Abstract]
- Biochim Biophys Acta Mol Basis Dis. 2025 Dec 31;1872(3):168150. [Abstract]
- J Mol Med (Berl). 2025 Aug 19. [Abstract]
- J Cell Mol Med. 2025 Jul;29(14):e70733. [Abstract]
- Biochim Biophys Acta Mol Basis Dis. 2025 Jul 18;1871(8):167990. [Abstract]
- Biochim Biophys Acta Mol Basis Dis. 2025 Jun;1871(5):167786. [Abstract]
- J Cell Mol Med. 2024 Aug;28(16):e70022. [Abstract]
- Biochim Biophys Acta Mol Basis Dis. 2024 Feb 9;1870(4):167061. [Abstract]
- Bioengineered. 2022 Feb;13(2):2597-2609. [Abstract]
- Microorganisms. 2021 Feb 22;9(2):452. [Abstract]
- J Cell Mol Med. 2020 Apr;24(8):4748-4761. [Abstract]
- J Cell Mol Med. 2019 Nov;23(11):7449-7461. [Abstract]
- iScience. 2024 Jul 26;27(9):110594. [Abstract]
- Am J Physiol Heart Circ Physiol. 2018 Mar 1;314(3):H580-H592. [Abstract]
- J Funct Foods. 2023 Aug, 107, 105670.
- Biomedicines. 2026 Mar 11;14(3):623. [Abstract]
- Neuromolecular Med. 2025 Sep 15;27(1):64. [Abstract]
- Sci Rep. 2025 Jul 2;15(1):22796. [Abstract]
- Sci Rep. 2025 Feb 20;15(1):6200. [Abstract]
- Sci Rep. 2024 Dec 5;14(1):30379. [Abstract]
- Sci Rep. 2024 Apr 30;14(1):9960. [Abstract]
- Biomedicines. 2022 Dec 4;10(12):3131. [Abstract]
- Sci Rep. 2022 Jan 10;12(1):344. [Abstract]
- Cell Signal. 2025 Dec 16:139:112330. [Abstract]
- ESC Heart Fail. 2025 Sep 3. [Abstract]
- ACS Pharmacol Transl Sci. 2025 Jun 6;8(7):2048-2060. [Abstract]
- Cell Signal. 2025 Jun 27:111968. [Abstract]
- Biochim Biophys Acta Mol Cell Res. 2024 Dec;1871(8):119852. [Abstract]
- Cell Signal. 2024 Aug 20:111355. [Abstract]
- Cardiovasc Toxicol. 2024 Sep;24(9):889-903. [Abstract]
- Cell Signal. 2024 Jul 14:121:111296. [Abstract]
- Biochim Biophys Acta Mol Cell Res. 2024 Mar;1871(3):119661. [Abstract]
- Cell Signal. 2024 Jan:113:110974. [Abstract]
- Cell Signal. 2022 Aug 18;110443. [Abstract]
- J Proteome Res. 2025 Nov 18. [Abstract]
- Heliyon. 2023 May 26;9(6):e16619. [Abstract]
- Mol Cell Endocrinol. 2023 Jul 1:571:111938. [Abstract]
- Eur J Clin Invest. 2022 May 4;e13804. [Abstract]
- Biology (Basel). 2026 Jan 22;15(2):206. [Abstract]
- Clin Exp Hypertens. 2023 Dec 31;45(1):2284658. [Abstract]
- Clin Exp Hypertens. 2023 Dec 31;45(1):2208774. [Abstract]
- Exp Cell Res. 2023 May 1;426(1):113556. [Abstract]
- Cardiovasc Ther. 2025 Sep 13:2025:7230505. [Abstract]
- Toxicol Appl Pharmacol. 2025 Aug 21:504:117528. [Abstract]
- Am J Physiol Renal Physiol. 2024 Nov 1;327(5):F885-F898. [Abstract]
- Am J Physiol Renal Physiol. 2021 Mar 1;320(3):F273-F284. [Abstract]
- Cell Cycle. 2020 Oct;19(20):2734-2744. [Abstract]
- J Appl Physiol (1985). 2022 Jun 1;132(6):1460-1467. [Abstract]
- Hum Mol Genet. 2024 Aug 31:ddae122. [Abstract]
- Hum Exp Toxicol. 2022 Jan-Dec;41:9603271221136208. [Abstract]
- Naunyn Schmiedebergs Arch Pharmacol. 2026 Mar 9. [Abstract]
- Cardiovasc Drugs Ther. 2025 Nov 15. [Abstract]
- Front Biosci (Landmark Ed). 2025 Jun 25;30(6):37052. [Abstract]
- Kaohsiung J Med Sci. 2024 Jun;40(6):542-552. [Abstract]
- J Bioenerg Biomembr. 2025 Jul 11. [Abstract]
- Ren Fail. 2023 Dec;45(1):2230318. [Abstract]
- J Pharmacol Sci. 2019 Sep;141(1):70-78. [Abstract]
- Mol Biol Rep. 2025 Aug 11;52(1):815. [Abstract]
- Mol Biol Rep. 2024 Apr 15;51(1):506. [Abstract]
- Int J Biochem Cell Biol. 2020 Apr;121:105703. [Abstract]
- Arch Physiol Biochem. 2025 Nov 24:1-19. [Abstract]
- Mol Cell Biol. 2024;44(4):149-163. [Abstract]
- Immun Inflamm Dis. 2023 Feb;11(2):e765. [Abstract]
- Microvasc Res. 2022 Sep:143:104384. [Abstract]
- Microvasc Res. 2022 Mar:140:104299. [Abstract]
- Microvasc Res. 2020 Nov;132:104043. [Abstract]
- Exp Biol Med. 2020 Jun;245(11):983-993. [Abstract]
- PLoS One. 2025 Sep 9;20(9):e0331471. [Abstract]
- PLoS One. 2024 Jul 25;19(7):e0306137. [Abstract]
- PLoS One. 2023 Sep 12;18(9):e0291469. [Abstract]
- Epigenomics. 2022 Mar;14(5):227-241. [Abstract]
- Clin Exp Pharmacol Physiol. 2026 Feb;53(2):e70110. [Abstract]
- Acta Cardiol. 2026 Jan 20:1-10. [Abstract]
- J Radiat Res Appl Sci. 2025 Dec 1;19(1):102092.
- Aging Med (Milton). 2025 Oct 26;8(5):383-397. [Abstract]
- Dose Response. 2024 Oct 25;22(4):15593258241277919. [Abstract]
- Dose Response. 2024 Oct 29;22(4):15593258241298062. [Abstract]
- Gene. 2023 Nov 15:885:147705. [Abstract]
- Exp Ther Med. 2026 Feb 25;31(4):117. [Abstract]
- Artif Organs. 2025 Jul 5. [Abstract]
- BMC Cardiovasc Disord. 2025 Jan 6;25(1):7. [Abstract]
- BMC Cardiovasc Disord. 2021 May 31;21(1):266. [Abstract]
- Folia Histochem Cytobiol. 2026;64(1):60-74. [Abstract]
- J Mol Histol. 2025 Sep 3;56(5):290. [Abstract]
- Biochem Biophys Res Commun. 2025 May 8:770:151957. [Abstract]
- Biochem Biophys Res Commun. 2025 Apr 1:755:151566. [Abstract]
- Biochem Biophys Res Commun. 2025 Jan:745:151256. [Abstract]
- Biochem Biophys Res Commun. 2024 Jul 26:735:150456. [Abstract]
- Biochem Biophys Res Commun. 2024 Jan 22:693:149375. [Abstract]
- Biochem Biophys Res Commun. 2021 Jun 11:557:77-84. [Abstract]
- Biochem Biophys Res Commun. 2021 May 7:552:84-90. [Abstract]
- Cardiovasc Diagn Ther. 2020 Apr;10(2):107-123. [Abstract]
- Physiol Res. 2020 Nov 16;69(5):813-822. [Abstract]
- J Neurovirol. 2025 Mar 26. [Abstract]
- Nephrology (Carlton). 2019 Nov;24(11):1103-1114. [Abstract]
- In Vitro Cell Dev Biol Anim. 2025 Apr 14. [Abstract]
- Peptide Sci. 2025 Feb 25.
- Cardiovasc Innov Appl. 2023 Sep 13.
- Int Heart J. 2025 May 31;66(3):485-496. [Abstract]
- Int Heart J. 2024;65(3):528-536. [Abstract]
- J Vis Exp. 2025 May 16:(219). [Abstract]
- Arch Biol Sci. 2021 Jun.
- bioRxiv. 2026 Jun 19.
- SSRN. 2026 Mar 20.
- Res Sq. 2026 Mar 25.
- SSRN. 2025 Aug 13.
- medRxiv. 2025 May 21.
- J Appl Pharm Sci. 2025 Jun;15(06):277-294.
- bioRxiv. 2024 November 03.
- Res Sq. 2024 Jun 27.
- SSRN. 2024 Mar 8.
- bioRxiv. 2023 Oct 20.
- Patent. US20230071726A1.
- Patent. US20230068165A1.
- SSRN. 2023 Feb 14.
- Research Square Print. 2022.
- Oxid Med Cell Longev. 2022 Feb 17:2022:3698219. [Abstract]
- J Healthc Eng. 2022 Jan 5:2022:1473597. [Abstract]
- Patent. US20210277021A1.
- bioRxiv. 2020 Mar.
- Oxid Med Cell Longev. 2019 Nov 23;2019:4025496. [Abstract]
-
WB
-
WB
-
RT-PCR
-
WB
-
WB
Voir tous les produits spécifiques à Isoform Angiotensin Receptor
More
Activité biologique
|
AT2 Receptor |
AT1 Receptor |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CHO | IC50 |
1.5 nM
Compound: Angiotensin II
|
Compound was evaluated in a binding assay using Chinese hamster ovary (CHO) cells stably expressing the rat Angiotensin II receptor, type 1
Compound was evaluated in a binding assay using Chinese hamster ovary (CHO) cells stably expressing the rat Angiotensin II receptor, type 1
|
[PMID: 10052967] |
| CHO | IC50 |
1.5 nM
Compound: Ang II
|
In vitro inhibitory activity against rat Angiotensin II receptor, type 1 expressed in CHO cells
In vitro inhibitory activity against rat Angiotensin II receptor, type 1 expressed in CHO cells
|
[PMID: 10579816] |
| CHO | EC50 |
0.52 nM
Compound: AngII
|
Agonist activity at human AT1 receptor transfected in CHO cells co-expressing Galpha16-mtAEQ assessed as induction of intracellular Ca2+ mobilization by bioluminescence assay
Agonist activity at human AT1 receptor transfected in CHO cells co-expressing Galpha16-mtAEQ assessed as induction of intracellular Ca2+ mobilization by bioluminescence assay
|
[PMID: 26824643] |
| HEK293 | IC50 |
8 x 10-11 M
Compound: Angiotensin-II
|
Displacement of [125I]CGP 42112A from human recombinant AT2 receptor expressed in HEK293 cells measured after 4 hrs by scintillation counting method
Displacement of [125I]CGP 42112A from human recombinant AT2 receptor expressed in HEK293 cells measured after 4 hrs by scintillation counting method
|
[PMID: 27876250] |
Most of the known actions of Angiotensin II (Ang II) are mediated by AT1 receptors, the AT2 receptor contributes to the regulation of blood pressure and renal function[1]
.
Angiotensin II raises blood pressure (BP) by a number of actions, the most important ones being vasoconstriction, sympathetic nervous stimulation, increased aldosterone biosynthesis and renal actions. Other Angiotensin II actions include induction of growth, cell migration, and mitosis of vascular smooth muscle cells, increased synthesis of collagen type I and III in fibroblasts, leading to thickening of the vascular wall and myocardium, and fibrosis. These actions are mediated by type 1 Ang II receptors (AT1)[2].
Angiotensin II (1 nM) induces the expression of LOX-1 and VEGF and enhances capillary formation from human coronary endothelial cells in Matrigel assay. Angiotensin II -mediated expression of LOX-1 and VEGF, capillary formation, intracellular reactive oxygen species generation, and phosphorylation of p38 as well as p44/42 mitogen-activated protein kinases, are suppressed by anti-LOX-1 antibody, nicotinamide-adenine dinucleotide phosphate oxidase inhibitor apocynin and the Ang II type 1 receptor blocker Losartan, but not by the Ang II type 2 receptor blocker PD123319[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Please do not refer to only one article to determine the experimental conditions. It is recommended to determine the optimal experimental conditions (animal strain, age, dosage, frequency and cycle, detection time and indicators, etc.) through preliminary experiments before the formal experiment.
Angiotensin II is internalized by various cell types through receptor-mediated endocytosis and is highly enriched in tissues such as the heart, kidney, and adrenal glands. The concentration in skeletal muscle tissue is 8%-41% of the plasma concentration, 64%-150% in the heart, 340%-550% in the kidney, and as high as 680%-2100% in the adrenal gland. It takes only about 5 minutes for Angiotensin II in plasma to reach a steady-state concentration, while it takes 30-60 minutes to reach a steady-state concentration in tissues. The half-life of Angiotensin II in the circulation system is extremely short (about 0.5 minutes), while in the heart, kidney, and adrenal tissues, the in vivo half-life of Angiotensin II formed after endocytosis is significantly extended to about 15 minutes[6]. Angiotensin II human can be used to induce models of hypertension, cardiac hypertrophy and abdominal aortic aneurysm[6][7][8][9].
Administration: 800 ng/kg/min, 0.003 mL/min • 7 days • sc, osmotic pump implanted subcutaneously
Administration: 2 μg/kg/min • 4 weeks • sc, osmotic pump implanted subcutaneously
Appearance monitoring: cardiac hypertrophy and fibrosis.
Administration: 500 or 1000 ng/min/kg • s.c. • 28 days
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Asp-Arg-Val-Tyr-Ile-His-Pro-Phe
DRVYIHPF
Chemical Information
-
CAS No. 4474-91-3
-
Appearance Solid
-
Masse moléculaire 1046.18
-
Formule C50H71N13O12
-
Color White to off-white
-
Synonyms
Angiotensin II; Ang II; DRVYIHPF
-
Structure Classification
-
Initial Source
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Sealed storage, away from moisture and light, under nitrogen
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)
Publications (224)
-
Journal Impact Factor
-
Most Recent
-
Cell Metab
Gut microbiota-derived isovaleric acid alleviates atrial fibrillation by suppressing GSDME-dependent pyroptosis. [Abstract]2026 Feb 3;38(2):370-387.e10. PMID: 41638192 -
Cell Stem Cell
Targeting ECM-producing cells with CAR-T therapy alleviates fibrosis in chronic kidney disease. [Abstract]2025 Sep 4;32(9):1390-1402.e9. PMID: 40848726 -
Nat Aging
Aging induces region-specific dysregulation of hormone synthesis in the primate adrenal gland. [Abstract]2024 Mar;4(3):396-413. PMID: 38503993 -
Cell Host Microbe
Gut microbiome dysbiosis contributes to abdominal aortic aneurysm by promoting neutrophil extracellular trap formation. [Abstract]2022 Oct 12;30(10):1450-1463.e8. PMID: 36228585 -
Circ Res
BMAL1-Downregulation Aggravates Porphyromonas Gingivalis-Induced Atherosclerosis by Encouraging Oxidative Stress. [Abstract]2020 Mar 13;126(6):e15-e29. PMID: 32078488 -
ACS Nano
Nanoparticle-Driven Controllable Mitochondrial Regulation through Lysosome-Mitochondria Interactome. [Abstract]2022 Aug 23;16(8):12553-12568. PMID: 35876466 -
Nat Commun
Cardiomyocyte-derived USP13 protects hearts from hypertrophy via deubiquitinating and stabilizing STAT1 in male mice. [Abstract]2025 Jul 1;16(1):5927. PMID: 40593642 -
Nat Commun
Endothelial Sp1/Sp3 are essential to the effect of captopril on blood pressure in male mice. [Abstract]2023 Sep 21;14(1):5891. PMID: 37735515 -
Nat Commun
The RalGAPα1-RalA signal module protects cardiac function through regulating calcium homeostasis. [Abstract]2022 Jul 25;13(1):4278. PMID: 35879328 -
Cell Death Differ
RNF220 mediates K63-linked polyubiquitination of STAT3 and aggravates pathological cardiac hypertrophy. [Abstract]2025 Nov 11. PMID: 41219491 -
Acta Pharm Sin B
USP25 ameliorates vascular remodeling by deubiquitinating FOXO3 and promoting autophagic degradation of FOXO3. [Abstract]2025 Mar;15(3):1643-1658. PMID: 40370563 -
Sci Transl Med
Extravascular administration of IGF1R antagonists protects against aortic aneurysm in rodent and porcine models. [Abstract]2024 May;16(745):eadh1763. PMID: 38691618 -
Acta Pharm Sin B
Atractylenolide-I covalently binds to CYP11B2, selectively inhibits aldosterone synthesis, and improves hyperaldosteronism. [Abstract]2022 Jan;12(1):135-148. PMID: 35127376 -
Sci Transl Med
Erythropoietin promotes abdominal aortic aneurysms in mice through angiogenesis and inflammatory infiltration. [Abstract]2021 Jul 21;13(603):eaaz4959. PMID: 34290056
Angiotensin II human purchased from MedChemExpress. Usage Cited in: Sci Transl Med. 2021 Jul 21;13(603):eaaz4959. [Abstract]
Cultured human renal 786-O cells were stimulated with vehicle, AngII (50 μM), AngII + Telmisartan (1 μM), AngII + PD123319 (50 μM) for 12 hrs. Cells were harvested and EPO protein abundance was detected by Western blot.
Angiotensin II human purchased from MedChemExpress. Usage Cited in: Sci Transl Med. 2021 Jul 21;13(603):eaaz4959. [Abstract]
SMC was stimulated with vehicle and AngII of 10-8 M, 10-7 M, 10-6 M,10-5 M and 10-4 M, respectively, for 24 hrs. Cells were harvested and EPO protein abundance measured by Western blot.
-
Adv Sci (Weinh)
LncRNA Foxo6os as a Novel " Scaffold" Mediates MYBPC3 in Combating Pathological Cardiac Hypertrophy and Heart Failure. [Abstract]2025 Jun 23:e07365. PMID: 40548957 -
Theranostics
2026 Feb 4;16(8):4452-4470. PMID: 41695487 -
-
Sci Adv
Cardiomyocyte-derived YOD1 promotes pathological cardiac hypertrophy by deubiquitinating and stabilizing STAT3. [Abstract]2025 Jun 27;11(26):eadu8422. PMID: 40561034 -
Med
Large-scale quantitative metabolomics and mass spectrometry imaging define the metabolic atlas in human acute type A aortic dissection. [Abstract]2026 Mar 27:101078. PMID: 41903544 -
-
Biomark Res
Deubiquitinase OTUD7B stabilizes HNF4α to alleviate pressure overload-induced cardiac hypertrophy by regulating fatty acid oxidation and inhibiting ferroptosis. [Abstract]2025 Mar 29;13(1):53. PMID: 40158182 -
Cell Rep Med
Targeting USP21 to inhibit abdominal aortic aneurysm progression by suppressing the phenotypic transition of vascular smooth muscle cells. [Abstract]2025 Sep 16;6(9):102328. PMID: 40925375 -
Pharmacol Res
Plant-derived nanovesicles as novel nanotherapeutics for alleviating endothelial cell senescence-associated vascular remodeling induced by hypertension. [Abstract]2025 Apr:214:107675. PMID: 40015387 -
Pharmacol Res
Piezo2 channel in nodose ganglia neurons is essential in controlling hypertension in a pathway regulated directly by Nedd4-2. [Abstract]2021 Feb:164:105391. PMID: 33352230 -
Cell Mol Biol Lett
METTL3 mediates Ang-II-induced cardiac hypertrophy through accelerating pri-miR-221/222 maturation in an m6A-dependent manner. [Abstract]2022 Jul 14;27(1):55. PMID: 35836108 -
Int J Biol Sci
Macrophage-derived S100A9 promotes diabetic cardiomyopathy by disturbing mitochondrial quality control via STAT3 activation. [Abstract]2025 Apr 22;21(7):3061-3080. PMID: 40384874 -
Food Chem
Ultrasound-assisted one-step extraction of safflower red and yellow pigments by natural ternary deep eutectic solvents: Extraction optimization and mechanism, separation and biological activities of pigments. [Abstract]2025 Dec 2:499:147383. PMID: 41352148 -
Ultrason Sonochem
Unlocking the potential of garlic by-product protein: Ultrasound-induced structural modification and fabrication of an ACE inhibitory peptide targeting endothelial dysfunction. [Abstract]2025 Oct 20:123:107642. PMID: 41151420 -
J Nucl Med
How Rapidly Does the FAPI PET Signal Reverse Following Therapy? Assessing the FAPI PET Signal in Hypertensive Cardiac Injury and Fibrosis in Mice. [Abstract]2025 Sep 11:jnumed.124.268860. PMID: 40935615 -
-
Chin Chem Lett
Nanokit coupled electrospray ionization mass spectrometry for analysis of angiotensin converting enzyme 2 activity in single living cell. [Abstract]2023 Mar;34(3):107522. PMID: 35602918 -
-
Int J Biol Macromol
Long noncoding RNA FGD5-AS1-encoded micropeptides improve right heart functions of pulmonary arterial hypertension through restricting the synthesis of hyaluronic acid. [Abstract]2025 Aug;320(Pt 4):146018. PMID: 40669641 -
Acta Pharmacol Sin
BMP1 inhibitor UK383367 improves MI-induced cardiac remodeling and fibrosis in mice via ameliorating macrophage polarization and mitochondrial dysfunction. [Abstract]2025 Sep 2. PMID: 40897852 -
Acta Pharmacol Sin
Endothelial FOSL1 drives angiotensin II-induced myocardial injury via AT1R-upregulated MYH9. [Abstract]2025 Apr;46(4):922-939. PMID: 39592734 -
Acta Pharmacol Sin
JOSD2 inhibits angiotensin II-induced vascular remodeling by deubiquitinating and stabilizing SMAD7. [Abstract]2025 May;46(5):1275-1288. PMID: 39833306 -
Acta Pharmacol Sin
Endothelial deubiquinatase YOD1 mediates Ang II-induced vascular endothelial-mesenchymal transition and remodeling by regulating β-catenin. [Abstract]2024 Aug;45(8):1618-1631. PMID: 38641745 -
Acta Pharmacol Sin
Chronic infusion of ELABELA alleviates vascular remodeling in spontaneously hypertensive rats via anti-inflammatory, anti-oxidative and anti-proliferative effects. [Abstract]2022 Oct;43(10):2573-2584. PMID: 35260820 -
Acta Pharmacol Sin
β-Arrestin2 deficiency attenuates oxidative stress in mouse hepatic fibrosis through modulation of NOX4. [Abstract]2021 Jul;42(7):1090-1100. PMID: 33116250 -
EMBO Mol Med
RBMS1 orchestrates cardiac hypertrophy by facilitating CTTN splice-switching and sarcomere dynamics. [Abstract]2025 Dec;17(12):3555-3585. PMID: 41214391 -
Phytomedicine
Mangiferin attenuates Ang II-induced abdominal aortic aneurysm by blocking Lys591-mediated nuclear translocation of STAT3. [Abstract]2025 Oct:146:157101. PMID: 40737845 -
Phytomedicine
13-Methylpalmatine alleviates bleomycin-induced pulmonary fibrosis by suppressing the ITGA5/TGF-β/Smad signaling pathway. [Abstract]2025 May:140:156545. PMID: 40023972 -
Phytomedicine
Sinapine targeting PLCβ3 EF hands disrupts Gαq-PLCβ3 interaction and ameliorates cardiovascular diseases. [Abstract]2024 Apr:126:155200. PMID: 38387273 -
Phytomedicine
Xin-Ji-Er-Kang protects myocardial and renal injury in hypertensive heart failure in mice. [Abstract]2021 Oct:91:153675. PMID: 34332285 -
Hypertension
2025 Sep;82(9):1505-1519. PMID: 40677234 -
Br J Pharmacol
Angiotensin II-induced phosphorylation of CHK1 at serine-280 drives cardiac remodelling by direct phosphorylation of JAK1, thus activating JAK1-STAT signalling in murine cardiomyocytes. [Abstract]2025 Aug 24. PMID: 40850933 -
J Transl Med
Betulinic acid as a novel AT1R inhibitor: attenuation of liver fibrosis via modulation of endothelial-mesenchymal transition in chronic hepatic injury. [Abstract]2025 Nov 13;23(1):1282. PMID: 41233877 -
Biomed Pharmacother
Tanshinol alleviates ischemia-induced myocardial fibrosis via targeting ERK2 and disturbing the intermolecular autophosphorylation of ERK2Thr188. [Abstract]2023 Dec:168:115729. PMID: 37862964 -
Biomed Pharmacother
Dapagliflozin attenuates myocardial hypertrophy via activating the SIRT1/HIF-1α signaling pathway. [Abstract]2023 Sep:165:115125. PMID: 37421782 -
Cell Death Discov
Anti-fibrotic mechanism of SPP1 knockdown in atrial fibrosis associates with inhibited mitochondrial DNA damage and TGF-β/SREBP2/PCSK9 signaling. [Abstract]2022 May 4;8(1):246. PMID: 35508610 -
Cell Death Discov
The lncRNA MIAT regulates CPT-1a mediated cardiac hypertrophy through m6A RNA methylation reading protein Ythdf2. [Abstract]2022 Apr 5;8(1):167. PMID: 35383152 -
Clin Transl Med
Angiotensin receptor blockers retard the progression and fibrosis via inhibiting the viability of AGTR1+ CAFs in intrahepatic cholangiocarcinoma. [Abstract]2023 Mar;13(3):e1213. PMID: 36855786 -
Elife
Activation of transient receptor potential vanilloid 4 is involved in pressure overload-induced cardiac hypertrophy. [Abstract]2022 Jun 22:11:e74519. PMID: 35731090 -
Phytother Res
Betulin Protects Against Cardiac Hypertrophy by Improving AMPK/Nrf2-Dependent Mitochondrial Function. [Abstract]2026 May;40(5):2878-2894. PMID: 41804091 -
Cell Biosci
LARP1 acts as a key mediator in preventing angiotensin II-induced cardiac dysfunction and fibrosis. [Abstract]2025 Oct 22;15(1):143. PMID: 41126333 -
Cell Mol Life Sci
Macrophage Dectin-1 mediates Ang II renal injury through neutrophil migration and TGF-β1 secretion. [Abstract]2023 Jun 20;80(7):184. PMID: 37340199 -
EMBO Rep
Mouse endothelial OTUD1 promotes angiotensin II-induced vascular remodeling by deubiquitinating SMAD3. [Abstract]2023 Mar 6;24(3):e56135. PMID: 36579465 -
Talanta
A robust polymetallic-coated sheathless interface with high acid and alkali resistance for coupling capillary electrophoresis with mass spectrometry. [Abstract]2024 Oct 14:282:127045. PMID: 39418980 -
JCI Insight
Endothelial cell prostaglandin E2 receptor EP4 is essential for blood pressure homeostasis. [Abstract]2020 Jul 9;5(13):e138505. PMID: 32641583 -
-
Chin Med
HuoXue QianYang QuTan recipe attenuates myocardial hypertrophy in obese hypertensive rats by regulating MPC1/MCT4 mediated pyruvate-lactate metabolic axis. [Abstract]2025 Oct 23;20(1):180. PMID: 41131633 -
Atherosclerosis
Valine acts as an early biomarker and exacerbates pathological cardiac hypertrophy by impairing mitochondrial quality control. [Abstract]2025 Apr 26:405:119216. PMID: 40318256 -
Acta Physiol
Tacrolimus Induced Hypertension and Vascular Remodeling Includes Mechanisms of Cellular Senescence-The Protective Effect of Valsartan. [Abstract]2026 Apr;242(4):e70189. PMID: 41814130 -
Biochem Pharmacol
2025 Aug 8;242(Pt 1):117218. PMID: 40784571 -
Biochem Pharmacol
LncRNA SNHG14 drives angiotensin-induced abdominal aortic aneurysm progression by regulating autophagy via the miR-27b-3p/Wnt/β-catenin/c-Myc axis. [Abstract]2025 Aug 19;242(Pt 1):117252. PMID: 40840634 -
Biochem Pharmacol
Indole selectively suppresses aldosterone overproduction via binding to the catalytic site of CYP11B2. [Abstract]2025 Jul 26;242(Pt 1):117190. PMID: 40721010 -
Biochem Pharmacol
2025 Apr:234:116800. PMID: 39952331 -
Biochem Pharmacol
S-adenosylmethionine attenuates angiotensin II-induced aortic dissection formation by inhibiting vascular smooth muscle cell phenotypic switch and autophagy. [Abstract]2024 Jan:219:115967. PMID: 38065291 -
Biochem Pharmacol
Macrophage scavenger receptor A1 antagonizes abdominal aortic aneurysm via upregulating IRG1. [Abstract]2023 Jul:213:115631. PMID: 37257722 -
Mol Cell Proteomics
2025 Feb 5:100922. PMID: 39921206 -
Mar Drugs
Novel pH-Responsive PSS-Loaded Chitosan Matrix Nanoparticles Ameliorate Pressure Overload-Induced Cardiac Hypertrophy. [Abstract]2025 Sep 19;23(9):365. PMID: 41003333 -
Inflammopharmacology
Carnosol mitigates Ang II-stimulated vascular injury and oxidative stress by directly binding to FAK and inhibiting its activation. [Abstract]2025 Mar 27. PMID: 40146440 -
Cells
Perivascular Adipocytes' Adipogenesis Is Defined by Their Anatomical Location in the Descending Thoracic Aorta. [Abstract]2025 Apr 11;14(8):579. PMID: 40277904 -
Commun Biol
2025 Nov 29. PMID: 41318855 -
Commun Biol
Ursodeoxycholic acid alleviates aortic aneurysm and dissection through the intestinal farnesoid X receptor/ceramide synthase 2 axis. [Abstract]2025 Jul 5;8(1):1009. PMID: 40617906 -
Life Sci
Angiotensin II can trigger HSC-LX2 pyroptosis through both classical and non-classical pathways. [Abstract]2022 Oct 15:307:120878. PMID: 35961596 -
-
J Nutr Biochem
Food-derived chlorogenic acid prevents aortic aneurysm and dissection by nutritional restore branched-chain amino acid dyshomeostasis. [Abstract]2025 Dec 6:150:110211. PMID: 41360205 -
J Nutr Biochem
Alginate oligosaccharide alleviates vascular aging by upregulating glutathione peroxidase 7. [Abstract]2024 Apr:126:109578. PMID: 38216066 -
Int J Mol Sci
Accumulation of Renal Fibrosis in Hyperuricemia Rats Is Attributed to the Recruitment of Mast Cells, Activation of the TGF-β1/Smad2/3 Pathway, and Aggravation of Oxidative Stress. [Abstract]2023 Jun 29;24(13):10839. PMID: 37446016 -
Biomolecules
2026 Jan 7;16(1):98. PMID: 41594638 -
Pharmaceuticals (Basel)
Nicotinamide Mononucleotide (NMN) Improves the Senescence of Mouse Vascular Smooth Muscle Cells Induced by Ang II Through Activating p-AMPK/KLF4 Pathway. [Abstract]2025 Apr 9;18(4):553. PMID: 40283988 -
Biomolecules
Gasdermin D Inhibitor Necrosulfonamide Alleviates Angiotensin II-Induced Abdominal Aortic Aneurysms in Apolipoprotein E-Deficient Mice. [Abstract]2024 Jun 19;14(6):726. PMID: 38927129 -
Biomolecules
Inhibition of Wdr5 Attenuates Ang-II-Induced Fibroblast-to-Myofibroblast Transition in Cardiac Fibrosis by Regulating Mdm2/P53/P21 Pathway. [Abstract]2022 Oct 27;12(11):1574. PMID: 36358925 -
Front Pharmacol
Pharmacological suppression of Nedd4-2 rescues the reduction of Kv11.1 channels in pathological cardiac hypertrophy. [Abstract]2022 Aug 17:13:942769. PMID: 36059970 -
Front Pharmacol
Effects of the Local Bone Renin-Angiotensin System on Titanium-Particle-Induced Periprosthetic Osteolysis. [Abstract]2021 Jun 24:12:684375. PMID: 34248634 -
Eur J Pharmacol
Tadalafil protects against renal fibrosis after ischemia-reperfusion injury by inhibiting Akt/NF-κB signaling pathway. [Abstract]2025 Dec 15:1009:178388. PMID: 41271150 -
Int Immunopharmacol
NOX2-mediated reactive oxygen species contribute to angiotensin II-induced cardiac hypertrophy by promoting cardiomyocyte autophagy via Atg4B S-glutathionylation modification. [Abstract]2025 Sep 23:162:115163. PMID: 40618504 -
J Mol Cell Cardiol
Elevated KCa3.1 expression by angiotensin II via the ERK/NF-κB pathway contributes to atrial fibrosis. [Abstract]2025 May:202:133-143. PMID: 40122157 -
Eur J Pharmacol
Therapeutic inhibition of PHF21B attenuates pathological cardiac hypertrophy by inhibiting the BMP4/GSK3β/β-catenin axis. [Abstract]2025 Feb 1:177346. PMID: 39900327 -
Eur J Pharmacol
Terazosin attenuates abdominal aortic aneurysm formation by downregulating Peg3 expression to inhibit vascular smooth muscle cell apoptosis and senescence. [Abstract]2024 Apr 5:968:176397. PMID: 38331337 -
Int Immunopharmacol
Macrophage-derived GSDMD promotes abdominal aortic aneurysm and aortic smooth muscle cells pyroptosis. [Abstract]2024 Feb 15:128:111554. PMID: 38262162 -
Am J Physiol Cell Physiol
OTUD6A in tubular epithelial cells mediates Angiotensin II-induced kidney injury by targeting STAT3. [Abstract]2024 Feb 1;326(2):C400-C413. PMID: 38105755 -
Philos Trans R Soc Lond B Biol Sci
Human induced pluripotent stem cell-derived cardiac myocytes and sympathetic neurons in disease modelling. [Abstract]2023 Jun 19;378(1879):20220173. PMID: 37122212 -
Int Immunopharmacol
Taxifolin ameliorates abdominal aortic aneurysm by preventing inflammation and apoptosis and extracellular matrix degradation via inactivating TLR4/NF-κB axis. [Abstract]2023 Jun:119:110197. PMID: 37098322 -
Int Immunopharmacol
Phenylacetylglutamine increases the susceptibility of ventricular arrhythmias in heart failure mice by exacerbated activation of the TLR4/AKT/mTOR signaling pathway. [Abstract]2023 Mar:116:109795. PMID: 36736224 -
Int Immunopharmacol
Inhibition of MyD88 attenuates angiotensin II-induced hypertensive kidney disease via regulating renal inflammation. [Abstract]2022 Nov:112:109218. PMID: 36116148 -
Am J Physiol Cell Physiol
Comprehensive identification of signaling pathways for idiopathic pulmonary arterial hypertension. [Abstract]2020 May 1;318(5):C913-C930. PMID: 32159364 -
Hypertens Res
Endothelial-derived complement factor D contributes to endothelial dysfunction in malignant nephrosclerosis via local complement activation. [Abstract]2023 Jul;46(7):1759-1770. PMID: 37188751 -
J Physiol
Hyperglycaemia-induced reactive oxygen species production in cardiac ventricular myocytes differs among mammals. [Abstract]2025 May 11. PMID: 40349305 -
Eur J Cell Biol
The mechanical mechanism of angiotensin II induced activation of hepatic stellate cells promoting portal hypertension. [Abstract]2024 May 28;103(2):151427. PMID: 38820882 -
FASEB J
2026 Feb 15;40(3):e71524. PMID: 41631390 -
Mol Nutr Food Res
Salvianolic Acid A Protects Against Angiotensin II-Induced Hypertensive Kidney Disease by Targeting TLR4 and Inhibiting TLR4/Myd88/PI3K/AKT/NF-κB Pathway. [Abstract]2026 Jan;70(1):e70371. PMID: 41543314 -
J Cell Mol Med
Integrated Network Pharmacology, Single-Cell Transcriptomics Unveil the Mechanistic Role of Morusin in Aortic Dissection. [Abstract]2026 Jan;30(1):e70971. PMID: 41482800 -
Biochim Biophys Acta Mol Basis Dis
Osteopontin aggravates myocardial fibrosis by promoting phenotypic transition of cardiac fibroblasts via Hippo-YAP pathway. [Abstract]2025 Dec 31;1872(3):168150. PMID: 41478364 -
J Mol Med (Berl)
4-Hydroxychalcone alleviated Angiotensin II-induced atrial fibrillation via immunoproteasome-IKK-NF-κB signaling pathway modulation. [Abstract]2025 Aug 19. PMID: 40828375 -
J Cell Mol Med
Myeloid MyD88 Mediates Macrophage Infiltration and Activation in Ang II-Induced Cardiac Hypertrophy. [Abstract]2025 Jul;29(14):e70733. PMID: 40682481 -
Biochim Biophys Acta Mol Basis Dis
Activation of IRF2 signaling networks facilitates podocyte pyroptosis in lupus nephritis. [Abstract]2025 Jul 18;1871(8):167990. PMID: 40684959 -
Biochim Biophys Acta Mol Basis Dis
Silencing RGS7 attenuates atrial fibrillation progression by activating the cGMP-PKG signaling pathway. [Abstract]2025 Jun;1871(5):167786. PMID: 40086518 -
J Cell Mol Med
2024 Aug;28(16):e70022. PMID: 39205384 -
Biochim Biophys Acta Mol Basis Dis
Deubiquitinase OTUD6a drives cardiac inflammation and hypertrophy by deubiquitination of STING. [Abstract]2024 Feb 9;1870(4):167061. PMID: 38342418 -
Bioengineered
Chromodomain Helicase DNA Binding Protein 1-like, a negative regulator of Forkhead box O3a, promotes the proliferation and migration of Angiotensin II-induced vascular smooth muscle cells. [Abstract]2022 Feb;13(2):2597-2609. PMID: 35001835 -
Microorganisms
Supernatants of Bifidobacterium longum and Lactobacillus plantarum Strains Exhibited Antioxidative Effects on A7R5 Cells. [Abstract]2021 Feb 22;9(2):452. PMID: 33671556 -
J Cell Mol Med
Inhibition of Interleukin-6/glycoprotein 130 signalling by Bazedoxifene ameliorates cardiac remodelling in pressure overload mice. [Abstract]2020 Apr;24(8):4748-4761. PMID: 32164044 -
J Cell Mol Med
Silencing of NONO inhibits abdominal aortic aneurysm in apolipoprotein E-knockout mice via collagen deposition and inflammatory inhibition. [Abstract]2019 Nov;23(11):7449-7461. PMID: 31512366 -
iScience
Stearic acid alleviates aortic medial degeneration through maintaining mitochondrial dynamics homeostasis via inhibiting JNK/MAPK signaling. [Abstract]2024 Jul 26;27(9):110594. PMID: 39224510 -
Am J Physiol Heart Circ Physiol
Overexpression of the neuronal human (pro)renin receptor mediates angiotensin II-independent blood pressure regulation in the central nervous system. [Abstract]2018 Mar 1;314(3):H580-H592. PMID: 29350998 -
-
Biomedicines
The Metabolite Differences in Vascular Smooth Muscle Cells of Abdominal Aortic Aneurysm Revealed by Untargeted Metabolomics. [Abstract]2026 Mar 11;14(3):623. PMID: 41898270 -
Neuromolecular Med
Hypertension Induces Cognitive Impairment and Alterations of Acetylcholine Receptor mRNA Expression in the Hippocampus and Cortex of Mice. [Abstract]2025 Sep 15;27(1):64. PMID: 40947477 -
Sci Rep
SBK3 suppresses angiotensin II-induced cardiac hypertrophy by regulating mitochondrial metabolism. [Abstract]2025 Jul 2;15(1):22796. PMID: 40594551 -
Sci Rep
In vivo and in vitro investigations of schisandrin B against angiotensin II induced ferroptosis and atrial fibrosis by regulation of the SIRT1 pathway. [Abstract]2025 Feb 20;15(1):6200. PMID: 39979353 -
Sci Rep
A multi-omics approach identifies the key role of disorders of sphingolipid metabolism in Ang II-induced hypertensive cardiomyopathy myocardial remodeling. [Abstract]2024 Dec 5;14(1):30379. PMID: 39638825 -
Sci Rep
2024 Apr 30;14(1):9960. PMID: 38693222 -
Biomedicines
Angiotensin II Inhibits Adipogenic Differentiation and Promotes Mature Adipocyte Browning through the Corepressor CtBP1. [Abstract]2022 Dec 4;10(12):3131. PMID: 36551887
Angiotensin II human purchased from MedChemExpress. Usage Cited in: Biomedicines. 2022 Dec 4;10(12):3131. [Abstract]
Angiotensin II human (Ang II; 100 nM; 24 h) pretreatment significantly increases both the protein level of CtBP1 during 3T3-L1 adipogenesis.
Angiotensin II human purchased from MedChemExpress. Usage Cited in: Biomedicines. 2022 Dec 4;10(12):3131. [Abstract]
Angiotensin II human (Ang II; 100 nM; 24 h) pretreatment significantly increases both the mRNA level of CtBP1 during 3T3-L1 adipogenesis.
-
Sci Rep
Endothelial-derived extracellular microRNA-92a promotes arterial stiffness by regulating phenotype changes of vascular smooth muscle cells. [Abstract]2022 Jan 10;12(1):344. PMID: 35013491 -
Cell Signal
JOSD2 alleviates hypertensive renal disease through deubiquitinating AKT in renal tubular epithelial cells. [Abstract]2025 Dec 16:139:112330. PMID: 41412561 -
ESC Heart Fail
Pathogenic glycosyltransferase genes and potential therapeutic drugs in pressure overload-induced heart failure. [Abstract]2025 Sep 3. PMID: 40903443 -
ACS Pharmacol Transl Sci
Critical Residues in the Gβ Subunit Mediate Selective Recruitment of the Gαq Heterotrimer to Activated G Protein-Coupled Receptors. [Abstract]2025 Jun 6;8(7):2048-2060. PMID: 40672669 -
Cell Signal
Role of EZH2 in regulating c-Myc stability through the E3 ubiquitin ligase HUWE1 in heart failure and its mechanisms. [Abstract]2025 Jun 27:111968. PMID: 40582435 -
Biochim Biophys Acta Mol Cell Res
2024 Dec;1871(8):119852. PMID: 39357547 -
Cell Signal
Angiotensin II depends on hippo/YAP signaling to reprogram angiogenesis and promote liver fibrosis. [Abstract]2024 Aug 20:111355. PMID: 39173854 -
Cardiovasc Toxicol
Ciprofloxacin Accelerates Angiotensin-II-Induced Vascular Smooth Muscle Cells Senescence Through Modulating AMPK/ROS pathway in Aortic Aneurysm and Dissection. [Abstract]2024 Sep;24(9):889-903. PMID: 39138741 -
Cell Signal
TG2 participates in pulmonary vascular remodelling by regulating the senescence of pulmonary artery smooth muscle cells. [Abstract]2024 Jul 14:121:111296. PMID: 39009200 -
Biochim Biophys Acta Mol Cell Res
Murine double minute 2-mediated estrogen receptor 1 degradation activates macrophage migration inhibitory factor to promote vascular smooth muscle cell dedifferentiation and oxidative stress during thoracic aortic aneurysm progression. [Abstract]2024 Mar;1871(3):119661. PMID: 38218386 -
Cell Signal
PKD knockdown mitigates Ang II-induced cardiac hypertrophy and ferroptosis via the JNK/P53 signaling pathway. [Abstract]2024 Jan:113:110974. PMID: 37972803 -
Cell Signal
Angiotensin II induces podocyte metabolic reprogramming from glycolysis to glycerol-3-phosphate biosynthesis. [Abstract]2022 Aug 18;110443. PMID: 35988808 -
J Proteome Res
A Cluster of Potential Molecular Contributors in Myocardial-Tissue-Derived In Situ Proteomic Profiling Mediate Myocardial Hypertrophy Linked to Right Heart Dysfunction. [Abstract]2025 Nov 18. PMID: 41252162 -
Heliyon
Gasdermin D affects aortic vascular smooth muscle cell pyroptosis and Ang II-induced vascular remodeling. [Abstract]2023 May 26;9(6):e16619. PMID: 37303505 -
Mol Cell Endocrinol
Angiotensin II-induced calcium overload affects mitochondrial functions in cardiac hypertrophy by targeting the USP2/MFN2 axis. [Abstract]2023 Jul 1:571:111938. PMID: 37100191
Angiotensin II human purchased from MedChemExpress. Usage Cited in: Mol Cell Endocrinol. 2023 Jul 1:571:111938. [Abstract]
Angiotensin II human (Ang II; 1 μM; 48 h) increases the expression of MFN1, t-CaMKⅡ and p-CaMKⅡ and decreases the expression of SERCA2 in NMCMs.
-
Eur J Clin Invest
KLF4 prevented angiotensin II-induced smooth muscle cell senescence by enhancing autophagic activity. [Abstract]2022 May 4;e13804. PMID: 35506324 -
Biology (Basel)
Suppressing Endothelial-Mesenchymal Transition Through the Histone Deacetylase 1/GATA Binding Protein 4 Pathway: The Mechanism of Protocatechuic Acid Against Myocardial Fibrosis Revealed by an Integrated Study. [Abstract]2026 Jan 22;15(2):206. PMID: 41594941 -
Clin Exp Hypertens
The Long non-coding RNA MALAT1 functions as a competing endogenous RNA to regulate vascular remodeling by sponging miR-145-5p/HK2 in hypertension. [Abstract]2023 Dec 31;45(1):2284658. PMID: 38010958 -
Clin Exp Hypertens
Ghrelin improves endothelial function and reduces blood pressure in Ang II-induced hypertensive mice: Role of AMPK. [Abstract]2023 Dec 31;45(1):2208774. PMID: 37149883 -
Exp Cell Res
The p53/miR-29a-3p axis mediates the antifibrotic effect of leonurine on angiotensin II-stimulated rat cardiac fibroblasts. [Abstract]2023 May 1;426(1):113556. PMID: 36933858 -
Cardiovasc Ther
Fibroblast Activation Protein-Targeted CAR-T Cells Induce Apoptosis in Murine Cardiac Myofibroblasts. [Abstract]2025 Sep 13:2025:7230505. PMID: 40977952 -
Toxicol Appl Pharmacol
2025 Aug 21:504:117528. PMID: 40848917 -
Am J Physiol Renal Physiol
Anatomic and functional evidence for renal autonomic innervation in normotensive and hypertensive rats. [Abstract]2024 Nov 1;327(5):F885-F898. PMID: 39298550 -
Am J Physiol Renal Physiol
Activation of the RAS contributes to peritoneal fibrosis via dysregulation of low-density lipoprotein receptor. [Abstract]2021 Mar 1;320(3):F273-F284. PMID: 33427062 -
Cell Cycle
MG53/CAV1 regulates transforming growth factor-β1 signaling-induced atrial fibrosis in atrial fibrillation. [Abstract]2020 Oct;19(20):2734-2744. PMID: 33000676 -
J Appl Physiol (1985)
ACE2 gene combined with exercise training attenuates central AngII/AT1 axis function and oxidative stress in a prehypertensive rat model. [Abstract]2022 Jun 1;132(6):1460-1467. PMID: 35546127 -
Hum Mol Genet
TRIM25 activates Wnt/β-catenin signalling by destabilising MAT2A mRNA to drive thoracic aortic aneurysm development. [Abstract]2024 Aug 31:ddae122. PMID: 39216871 -
Hum Exp Toxicol
[Gly14]-Humanin inhibits an angiotensin II-induced vascular smooth muscle cell phenotypic switch via ameliorating intracellular oxidative stress. [Abstract]2022 Jan-Dec;41:9603271221136208. PMID: 36289015 -
Naunyn Schmiedebergs Arch Pharmacol
Small-molecule LF3 alleviates angiotensin II-induced cardiac dysfunction via attenuating cardiac fibrosis. [Abstract]2026 Mar 9. PMID: 41796236 -
Cardiovasc Drugs Ther
GDF11 Regulates Vascular Smooth Muscle Cell Phenotype Switching to Prevent Aortic Aneurysm Formation. [Abstract]2025 Nov 15. PMID: 41240221 -
Front Biosci (Landmark Ed)
2025 Jun 25;30(6):37052. PMID: 40613298 -
Kaohsiung J Med Sci
Proteasome inhibitor bortezomib prevents proliferation and migration of pulmonary arterial smooth muscle cells. [Abstract]2024 Jun;40(6):542-552. PMID: 38682650 -
J Bioenerg Biomembr
WTAP Silencing protects human aortic smooth muscle cells from angiotensin II-induced senescence, apoptosis, ferroptosis, and inflammation by regulating PCSK9. [Abstract]2025 Jul 11. PMID: 40643726 -
Ren Fail
2023 Dec;45(1):2230318. PMID: 37427767 -
J Pharmacol Sci
Overexpression of microRNA-21 mediates Ang II-induced renal fibrosis by activating the TGF-β1/Smad3 pathway via suppressing PPARα. [Abstract]2019 Sep;141(1):70-78. PMID: 31611175 -
Mol Biol Rep
HSPA9/HMGB1 regulates myocardial fibrosis in atrial fibrillation via TGF-β1/Smad pathway and autophagy. [Abstract]2025 Aug 11;52(1):815. PMID: 40788381 -
Mol Biol Rep
Targeting myocardial inflammation: investigating the therapeutic potential of atrial natriuretic peptide in atrial fibrosis. [Abstract]2024 Apr 15;51(1):506. PMID: 38622341 -
Int J Biochem Cell Biol
Angiotensin II inhibits osteogenic differentiation of isolated synoviocytes by increasing DKK-1 expression. [Abstract]2020 Apr;121:105703. PMID: 32014499
Angiotensin II human purchased from MedChemExpress. Usage Cited in: Int J Biochem Cell Biol. 2020 Apr;121:105703. [Abstract]
HPMCs are treated with 5.6 mM glucose (NG) or with 236 mM glucose (HG), or 100 nM AngII (AngII), or 236 mM glucose plus 10 mM valsartan (HGþvalsartan), or 100 nM AngII plus 10 mM valsartan (AngIIþvalsartan) for 24 h. The protein levels of p-mTOR, mTOR, p-4EBP1, 4EBP1, p-S6K1, and S6K1 are examined by Western blot analysis.
-
Arch Physiol Biochem
Verbascoside attenuates angiotensin-induced hypertension by inhibiting endoplasmic reticulum stress via the Nur77/GFPT2/CHOP pathway. [Abstract]2025 Nov 24:1-19. PMID: 41284022 -
Mol Cell Biol
Effects of Phenylacetylglutamine on the Susceptibility of Atrial Fibrillation in Overpressure-Induced HF Mice. [Abstract]2024;44(4):149-163. PMID: 38725392 -
Immun Inflamm Dis
PON2 ameliorates Ang II-induced cardiomyocyte injury by targeting the CANX/NOX4 signaling pathway. [Abstract]2023 Feb;11(2):e765. PMID: 36840500 -
Microvasc Res
NLRP3 inflammasome contributes to endothelial dysfunction in angiotensin II-induced hypertension in mice. [Abstract]2022 Sep:143:104384. PMID: 35618036 -
Microvasc Res
Inhibition of XIST attenuates abdominal aortic aneurysm in mice by regulating apoptosis of vascular smooth muscle cells through miR-762/MAP2K4 axis. [Abstract]2022 Mar:140:104299. PMID: 34942175 -
Microvasc Res
2020 Nov;132:104043. PMID: 32707048 -
Exp Biol Med
Valsartan ameliorates high glucose-induced peritoneal fibrosis by blocking mTORC1 signaling. [Abstract]2020 Jun;245(11):983-993. PMID: 32408765 -
PLoS One
1p-Enh-regulated CYP4B1 alleviates NNK-induced heart failure and lung cancer via the STAT3 pathway. [Abstract]2025 Sep 9;20(9):e0331471. PMID: 40924729 -
PLoS One
MICT ameliorates hypertensive nephropathy by inhibiting TLR4/NF-κB pathway and down-regulating NLRC4 inflammasome. [Abstract]2024 Jul 25;19(7):e0306137. PMID: 39052650 -
PLoS One
Fucoxanthin inhibits cardiac fibroblast transdifferentiation by alleviating oxidative stress through downregulation of BRD4. [Abstract]2023 Sep 12;18(9):e0291469. PMID: 37699016 -
Epigenomics
Promotional effects of HIF1α and KDM3A interaction on vascular smooth muscle cells in thoracic aortic dissection. [Abstract]2022 Mar;14(5):227-241. PMID: 35172598 -
Clin Exp Pharmacol Physiol
Kruppel-Like Factor 5 Modulates the Nuclear Factor Erythroid-2-Related Factor 2/Heme Oxygenase 1 Signalling Pathway to Regulate Vascular Smooth Muscle Cell Ferroptosis in Abdominal Aortic Aneurysm. [Abstract]2026 Feb;53(2):e70110. PMID: 41656496 -
Acta Cardiol
From inflammation to degeneration: role of MMPs, IL6, and TIMP-1 in systemic sclerosis and aortic dissection. [Abstract]2026 Jan 20:1-10. PMID: 41556204 -
-
Aging Med (Milton)
Visualization of OPN-Targeted Self-Assembled Micelles Encapsulated With an SIRT6 Activator and Doped Indocyanine Green for Attenuating Vascular Aging. [Abstract]2025 Oct 26;8(5):383-397. PMID: 41180385 -
Dose Response
Paeoniflorin Inhibits Atrial Fibrosis and Atrial Fibrillation in Angiotensin II-Infused Mice Through the PI3K-Akt Pathway. [Abstract]2024 Oct 25;22(4):15593258241277919. PMID: 39469468 -
Dose Response
Decrease of Prolylcarboxypeptidase Dose of Aqueous Humor is Involved in the Pathogenesis of Primary Open-Angle Glaucoma via Finetuning of the Local Ocular Renin-Angiotensin System. [Abstract]2024 Oct 29;22(4):15593258241298062. PMID: 39484664 -
Gene
ATF3 affects myocardial fibrosis remodeling after myocardial infarction by regulating autophagy and its mechanism of action. [Abstract]2023 Nov 15:885:147705. PMID: 37572799 -
Exp Ther Med
DKK1/SMDT1 participate in Ang II-induced mitochondrial injury of human smooth muscle cells in an abdominal aortic aneurysm cell model. [Abstract]2026 Feb 25;31(4):117. PMID: 41822196 -
Artif Organs
Comparison of the Construction Methods of Parathyroid Organoids and Functional Influence of Calcium on Organoids. [Abstract]2025 Jul 5. PMID: 40616330 -
BMC Cardiovasc Disord
Alantolactone mitigates the elevation of blood pressure in mice induced by angiotensin II by inhibiting calcium channel activation. [Abstract]2025 Jan 6;25(1):7. PMID: 39762727 -
BMC Cardiovasc Disord
KLK11 promotes the activation of mTOR and protein synthesis to facilitate cardiac hypertrophy. [Abstract]2021 May 31;21(1):266. PMID: 34059001 -
Folia Histochem Cytobiol
Ginsenoside Rg3 inhibits Ang II-induced cardiac fibrosis via the GLP-1 receptor signaling pathway. [Abstract]2026;64(1):60-74. PMID: 41874174 -
J Mol Histol
HIF-1α-mediated inhibition of the sFlt-1/sENG/TNF-α pathway promotes angiogenesis to ameliorate pre-eclampsia. [Abstract]2025 Sep 3;56(5):290. PMID: 40897907 -
Biochem Biophys Res Commun
Alleviation of fibrosis and oxidative stress in pressure overload-induced cardiac remodeling and heart failure via SIRT3 activation by colchicine. [Abstract]2025 May 8:770:151957. PMID: 40373382 -
Biochem Biophys Res Commun
TRPC1 downregulation enhances catecholamine secretion in adrenal chromaffin cells under metabolic syndrome conditions. [Abstract]2025 Apr 1:755:151566. PMID: 40043610 -
Biochem Biophys Res Commun
2025 Jan:745:151256. PMID: 39740402 -
Biochem Biophys Res Commun
Disruption of the interaction between caveolae and Piezo1 promotes pressure overload-induced cardiac remodeling. [Abstract]2024 Jul 26:735:150456. PMID: 39094230 -
Biochem Biophys Res Commun
The inhibition of FTO attenuates the antifibrotic effect of leonurine in rat cardiac fibroblasts. [Abstract]2024 Jan 22:693:149375. PMID: 38128243 -
Biochem Biophys Res Commun
Protective effects of 4-octyl itaconate against inflammatory response in angiotensin II-induced oxidative stress in human primary retinal pigment epithelium. [Abstract]2021 Jun 11:557:77-84. PMID: 33862463 -
Biochem Biophys Res Commun
Myogenin suppresses apoptosis induced by angiotensin II in human induced pluripotent stem cell-derived cardiomyocytes. [Abstract]2021 May 7:552:84-90. PMID: 33743352 -
Cardiovasc Diagn Ther
Kallistatin correlates with inflammation in abdominal aortic aneurysm and suppresses its formation in mice. [Abstract]2020 Apr;10(2):107-123. PMID: 32420091 -
Physiol Res
Apelin-13 regulates angiotensin ii-induced Cx43 downregulation and autophagy via the AMPK/mTOR signaling pathway in HL-1 cells. [Abstract]2020 Nov 16;69(5):813-822. PMID: 32901500 -
J Neurovirol
The OLR1/NF-κB feedback loop exacerbates HIV-1 Tat-induced microglial inflammatory response and neuronal apoptosis. [Abstract]2025 Mar 26. PMID: 40140148 -
Nephrology (Carlton)
Bioinformatic analysis reveals novel hub genes and pathways associated with hypertensive nephropathy. [Abstract]2019 Nov;24(11):1103-1114. PMID: 30298691 -
In Vitro Cell Dev Biol Anim
SPARC: a key mediator of apoptosis in human umbilical vein endothelial cells and its role in hypertension mechanism. [Abstract]2025 Apr 14. PMID: 40229525 -
-
-
Int Heart J
Decrease in Caveolae-Gαq Interaction Mediates Pressure Overload-Induced Cardiac Remodeling in Rats. [Abstract]2025 May 31;66(3):485-496. PMID: 40368774 -
Int Heart J
2024;65(3):528-536. PMID: 38825497 -
J Vis Exp
Murine Model of Thoracic Aortic Dissection Induced by Oral β-Aminopropionitrile and Subcutaneous Angiotensin II Infusion. [Abstract]2025 May 16:(219). PMID: 40455668 -
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Oxid Med Cell Longev
2022 Feb 17:2022:3698219. PMID: 35222797 -
J Healthc Eng
Study on Toll-Like Receptor 2-Mediated Inflammation-Induced Familial Hypertension Combined with Hyperlipemia and Its Mechanism. [Abstract]2022 Jan 5:2022:1473597. PMID: 35035808 -
-
-
Oxid Med Cell Longev
Upregulation of Transient Receptor Potential Canonical Type 3 Channel via AT1R/TGF- β 1/Smad2/3 Induces Atrial Fibrosis in Aging and Spontaneously Hypertensive Rats. [Abstract]2019 Nov 23;2019:4025496. PMID: 31871548
Solvant et solubilité
H2O : ≥ 10 mg/mL (9.56 mM)
DMSO : 10 mg/mL (9.56 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 2 mg/mL (1.91 mM); Clear solution; Need ultrasonic and warming and heat to 60°C
Add each solvent one by one: Saline
Solubility: ≥ 5 mg/mL (4.78 mM); Clear solution
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
Protocole
Mice[3]
(129×C57BL/6) F1 mice lacking AT1A receptors for Angiotensin II are used. The mice are fed 10 gm/day gelled 0.25% NaCl diet that contains all nutrients and water. After 1 week of baseline collections, the animals are implanted with osmotic minipumps infusing Angiotensin II and are returned to the metabolic cage for 5 more days. Urinary sodium content is determined by using an IL943 Automatic Flame photometer. After 28 days of Angiotensin II infusion, hearts are harvested, weighed, fixed in formalin, sectioned, and stained with Masson trichrome. All of the tissues are examined by a pathologist (P.R.) without knowledge of genotypes.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pureté et documentation
-
Fiche technique (296 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Portuguese - PT (394 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. de Gasparo M, et al. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev. 2000 Sep;52(3):415-72. [Content Brief]
[2]. Fyhrquist F, et al. Role of angiotensin II in blood pressure regulation and in the pathophysiology of cardiovascular disorders. J Hum Hypertens. 1995 Nov;9 Suppl 5:S19-24. [Content Brief]
[3]. Hu C, et al. Angiotensin II induces capillary formation from endothelial cells via the LOX-1 dependent redox-sensitive pathway. Hypertension. 2007;50(5):952-957. [Content Brief]
[4]. Nabah YN, et al. Angiotensin II induces neutrophil accumulation in vivo through generation and release of CXC chemokines. Circulation. 2004;110(23):3581-3586. [Content Brief]
[5]. Crowley SD, et al. Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proc Natl Acad Sci U S A. 2006 Nov 21;103(47):17985-90. [Content Brief]
[6]. van Kats JP, et al. Angiotensin II type 1 (AT1) receptor-mediated accumulation of angiotensin II in tissues and its intracellular half-life in vivo. Hypertension. 1997 Jul;30(1 Pt 1):42-9. [Content Brief]
[7]. Xue B, et al. Sex differences in the development of angiotensin II-induced hypertension in conscious mice. Am J Physiol Heart Circ Physiol. 2005 May;288(5):H2177-84. [Content Brief]
[8]. Matsui Y, et al. Role of osteopontin in cardiac fibrosis and remodeling in angiotensin II-induced cardiac hypertrophy. Hypertension. 2004 Jun;43(6):1195-201. [Content Brief]
[9]. Daugherty A, et al. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest. 2000 Jun;105(11):1605-12. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 0.9559 mL | 4.7793 mL | 9.5586 mL | 23.8965 mL |
| 5 mM | 0.1912 mL | 0.9559 mL | 1.9117 mL | 4.7793 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.